Search

Date 2021 Author/Creator Sebert, M.

1. Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients. (28th November 2021)

Authors:
Georgin‐Lavialle, S.; Terrier, B.; Guedon, A.F.; Heiblig, M.; Comont, T.; Lazaro, E.; Lacombe, V.; Terriou, L.; Ardois, S.; Bouaziz, J.‐D.; Mathian, A.; Le Guenno, G.; Aouba, A.; Outh, R.; Meyer, A.; Roux‐Sauvat, M.; Ebbo, M.; Zhao, L.P.; Bigot, A.; Jamilloux, Y.
Journal:
British journal of dermatology
Issue:
Volume 186:Number 3(2022)
Page Start:
564
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III: APR 246 PLUS AZACITIDINE (AZA) IN TP53 MUTATED (M) MDS AND AML. LONG TERM FOLLOW UP OF PHASE 2 STUDY BY THE GFM. (September 2021)

Authors:
Cluzeau, T.; Sebert, M.; Rahmé, R.; Cuzzubbo, S.; Walter-Petrich, A.; Peterlin, P.; Recher, C.; Stamatoullas, A.; Willems, L.; Raffoux, E.; Berthon, C.; Sallman, D.; Ades, L.; Fenaux, P.
Journal:
Leukemia research
Issue:
Volume 108(2021)Supplement
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search